Basilea Pharmaceutica Ltd.: FDA Accepts For Review The Complete Response Submission To Ceftobiprole NDA

Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the U.S. Food and Drug Administration (FDA) has accepted the response submitted by the sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (PRD) as complete.